Literature DB >> 21727765

Viral-associated thrombotic microangiopathies.

Rodrigo Lopes da Silva1.   

Abstract

Thrombotic microangiopathies encompass a group of disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia associated with hyaline thrombi (comprised primarily of platelet aggregates in the microcirculation), and varying degrees of end-organ failure. Many primary (genetic) and secondary etiological predisposing factors have been described-namely pregnancy, autoimmune disorders, cancer, drugs and antineoplastic therapy, bone marrow transplantation/solid organ transplantation, and infections. In the setting of infectious diseases, the association with Shiga or Shiga-like exotoxin of Escherichia coli 0157:h7 or Shigella dysenteriae type 1-induced typical hemolytic uremic syndrome is well known. Recently however, an increasing body of evidence suggests that viruses may also play an important role as trigger factors in the pathogenesis of thrombotic microangiopathies. This is a comprehensive review focusing on the current understanding of viral associated/induced endothelial stimulation and damage that ultimately leads to the development of this life-threatening multisystemic disorder.

Entities:  

Mesh:

Year:  2011        PMID: 21727765     DOI: 10.5144/1658-3876.2011.51

Source DB:  PubMed          Journal:  Hematol Oncol Stem Cell Ther


  24 in total

1.  Thrombotic microangiopathy with multiorgan involvement following COVID-19.

Authors:  Bhavika Gandhi; Deborah Jebakumar; Matthew Nickell; Mohanram Narayanan
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-11-05

2.  Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.

Authors:  Teresa Marta Cardesa-Salzmann; Bernhard Stephan; Arne Simon; Rhoikos Furtwängler; Dominik Schöndorf; Sabine Heine; Eyad Torfah; Margaux Lux; Sonja Meyer; Norbert Graf
Journal:  Clin Case Rep       Date:  2022-05-20

3.  Immune Complex Mediated Glomerulonephritis with Acute Thrombotic Microangiopathy following Newly Detected Hepatitis B Virus Infection in a Kidney Transplant Recipient.

Authors:  Tracey Salter; Hannah Burton; Sam Douthwaite; William Newsholme; Catherine Horsfield; Rachel Hilton
Journal:  Case Rep Transplant       Date:  2016-10-09

4.  Eculizumab in secondary atypical haemolytic uraemic syndrome.

Authors:  Teresa Cavero; Cristina Rabasco; Antía López; Elena Román; Ana Ávila; Ángel Sevillano; Ana Huerta; Jorge Rojas-Rivera; Carolina Fuentes; Miquel Blasco; Ana Jarque; Alba García; Santiago Mendizabal; Eva Gavela; Manuel Macía; Luis F Quintana; Ana María Romera; Josefa Borrego; Emi Arjona; Mario Espinosa; José Portolés; Carolina Gracia-Iguacel; Emilio González-Parra; Pedro Aljama; Enrique Morales; Mercedes Cao; Santiago Rodríguez de Córdoba; Manuel Praga
Journal:  Nephrol Dial Transplant       Date:  2017-03-01       Impact factor: 5.992

Review 5.  TTP-like syndrome: novel concept and molecular pathogenesis of endotheliopathy-associated vascular microthrombotic disease.

Authors:  Jae C Chang
Journal:  Thromb J       Date:  2018-08-11

6.  Cerebral venous sinus thrombosis sequel of COVID encephalitis; a rare presentation.

Authors:  Iqra Athar; Tariq Muhammad; Haris Majid; Neelma Naz Khattak; Mazhar Badshah
Journal:  Brain Hemorrhages       Date:  2021-07-16

7.  Thrombotic Microangiopathy: Multi-Institutional Review of Pediatric Patients Who Underwent HSCT.

Authors:  Archana Ramgopal; Shiva Sridar; Jignesh Dalal; Ramasubramanian Kalpatthi
Journal:  J Pers Med       Date:  2021-05-25

8.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08

9.  Dengue Fever-induced Thrombotic Microangiopathy: An Unusual Cause of Renal Failure.

Authors:  V Bhargava; P Gupta; R Kauntia; G Bajpai
Journal:  Indian J Nephrol       Date:  2017 Jul-Aug

Review 10.  Neurological associations of COVID-19.

Authors:  Mark A Ellul; Laura Benjamin; Bhagteshwar Singh; Suzannah Lant; Benedict Daniel Michael; Ava Easton; Rachel Kneen; Sylviane Defres; Jim Sejvar; Tom Solomon
Journal:  Lancet Neurol       Date:  2020-07-02       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.